Efficacy and safety of zuranolone co-initiated with an antidepressant in adults with major depressive disorder: results from the phase 3 CORAL study
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy and safety of zuranolone co-initiated with an antidepressant in adults with major depressive disorder: results from the phase 3 CORAL study
Authors
Keywords
-
Journal
NEUROPSYCHOPHARMACOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-10-24
DOI
10.1038/s41386-023-01751-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Zuranolone for the Treatment of Adults With Major Depressive Disorder: A Randomized, Placebo‐Controlled Phase 3 Trial
- (2023) Anita H. Clayton et al. AMERICAN JOURNAL OF PSYCHIATRY
- Glutamate and GABA Homeostasis and Neurometabolism in Major Depressive Disorder
- (2021) Ajay Sarawagi et al. Frontiers in Psychiatry
- Effect of Zuranolone vs Placebo in Postpartum Depression
- (2021) Kristina M. Deligiannidis et al. JAMA Psychiatry
- Antidepressant side effects and their impact on treatment outcome in people with major depressive disorder: an iSPOT-D report
- (2021) Taylor A. Braund et al. Translational Psychiatry
- Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic
- (2021) Damian F Santomauro et al. LANCET
- The effects of once- versus twice-weekly sessions on psychotherapy outcomes in depressed patients
- (2020) Sanne J. E. Bruijniks et al. BRITISH JOURNAL OF PSYCHIATRY
- National Prescription Patterns of Antidepressants in the Treatment of Adults With Major Depression in the US Between 1996 and 2015: A Population Representative Survey Based Analysis
- (2020) Yan Luo et al. Frontiers in Psychiatry
- Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant
- (2020) Saurabh S. Kokane et al. BEHAVIOURAL BRAIN RESEARCH
- Real-world patient experience with sexual dysfunction and antidepressant use in patients with self-reported depression: A cross-sectional survey study
- (2020) Paula L. Jacobsen et al. NEUROLOGY PSYCHIATRY AND BRAIN RESEARCH
- Allopregnanolone: From molecular pathophysiology to therapeutics. A historical perspective
- (2020) Steven M Paul et al. Neurobiology of Stress
- Prevalence of Depression Symptoms in US Adults Before and During the COVID-19 Pandemic
- (2020) Catherine K. Ettman et al. JAMA Network Open
- Preclinical characterization of zuranolone (SAGE-217), a selective neuroactive steroid GABAA receptor positive allosteric modulator
- (2020) Alison L. Althaus et al. NEUROPHARMACOLOGY
- Reduced default mode network functional connectivity in patients with recurrent major depressive disorder
- (2019) Chao-Gan Yan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- SAGE-217, A Novel GABAA Receptor Positive Allosteric Modulator: Clinical Pharmacology and Tolerability in Randomized Phase I Dose-Finding Studies
- (2019) Ethan Hoffmann et al. CLINICAL PHARMACOKINETICS
- Changes in the global burden of depression from 1990 to 2017: Findings from the Global Burden of Disease study
- (2019) Qingqing Liu et al. JOURNAL OF PSYCHIATRIC RESEARCH
- Trial of SAGE-217 in Patients with Major Depressive Disorder
- (2019) Handan Gunduz-Bruce et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis
- (2018) Andrea Cipriani et al. LANCET
- Network meta-analysis of antidepressants
- (2018) Irving Kirsch et al. LANCET
- Depression
- (2018) Gin S Malhi et al. LANCET
- Neuroactive Steroids. 2. 3α-Hydroxy-3β-methyl-21-(4-cyano-1H-pyrazol-1′-yl)-19-nor-5β-pregnan-20-one (SAGE-217): A Clinical Next Generation Neuroactive Steroid Positive Allosteric Modulator of the (γ-Aminobutyric Acid)A Receptor
- (2017) Gabriel Martinez Botella et al. JOURNAL OF MEDICINAL CHEMISTRY
- Has the rising placebo response impacted antidepressant clinical trial outcome? Data from the US Food and Drug Administration 1987-2013
- (2017) Arif Khan et al. World Psychiatry
- The clinical significance of drug-placebo differences
- (2017) I. Kirsch Epidemiology and Psychiatric Sciences
- Validation of the 17-item Hamilton Depression Rating Scale definition of response for adults with major depressive disorder using equipercentile linking to Clinical Global Impression scale ratings: analysis of Pharmacogenomic Research Network Antidepressa
- (2016) William V. Bobo et al. HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL
- Ketamine Treatment and Global Brain Connectivity in Major Depression
- (2016) Chadi G Abdallah et al. NEUROPSYCHOPHARMACOLOGY
- Empirically derived criteria cast doubt on the clinical significance of antidepressant-placebo differences
- (2015) Joanna Moncrieff et al. Contemporary Clinical Trials
- The heterogeneity of “major depression”
- (2015) DAVID GOLDBERG World Psychiatry
- ANXIETY IN MAJOR DEPRESSION AND CEREBROSPINAL FLUID FREE GAMMA-AMINOBUTYRIC ACID
- (2014) J. John Mann et al. DEPRESSION AND ANXIETY
- Residual symptoms and functioning in depression, does the type of residual symptom matter? A post-hoc analysis
- (2013) Irene Romera et al. BMC Psychiatry
- How much psychotherapy is needed to treat depression? A metaregression analysis
- (2013) Pim Cuijpers et al. JOURNAL OF AFFECTIVE DISORDERS
- What does the HAMD mean?
- (2013) Stefan Leucht et al. JOURNAL OF AFFECTIVE DISORDERS
- Key multiplicity issues in clinical drug development
- (2012) Alex Dmitrienko et al. STATISTICS IN MEDICINE
- Cross-national epidemiology of DSM-IV major depressive episode
- (2011) Evelyn Bromet et al. BMC Medicine
- Exploratory Analyses of Efficacy Data From Major Depressive Disorder Trials Submitted to the US Food and Drug Administration in Support of New Drug Applications
- (2011) Ni A. Khin et al. JOURNAL OF CLINICAL PSYCHIATRY
- Early Response and Remission as Predictors of a Good Outcome of a Major Depressive Episode at 12-Month Follow-Up
- (2011) Antonio Ciudad et al. JOURNAL OF CLINICAL PSYCHIATRY
- Epidemiologic heterogeneity of common mood and anxiety disorders over the lifecourse in the general population: a systematic review
- (2009) Arijit Nandi et al. BMC Psychiatry
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now